Last reviewed · How we verify
Dupilumab - Standard Dose
At a glance
| Generic name | Dupilumab - Standard Dose |
|---|---|
| Also known as | Dupixent |
| Sponsor | Johns Hopkins University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid (PHASE2, PHASE3)
- Dupilumab De-escalation in Pediatric Atopic Dermatitis (PHASE4)
- Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis
- Dupilumab Therapy for EGIDs
- SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
- A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps (PHASE4)
- Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
- Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dupilumab - Standard Dose CI brief — competitive landscape report
- Dupilumab - Standard Dose updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI